Kymab granted leave to appeal to the UK Supreme Court

Cambridge, UK; 30 November 2018: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that it has received permission to appeal the decision of the UK Court of Appeal to overturn the decision of the High Court trial judge, Mr. Justice Henry Carr, to revoke two patents (European Patent EP(UK) 1 360 287 and EP(UK) 2 264 163) owned by Regeneron.